Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

CreditFlow: End of Day (Europe IG)

IGC European Market: Commentary - Close
  • € IG WTD (€32.25bn) is 100.3% of our ‘Supply Survey’ forecast of €32.16bn
  • CreditFlow ‘Supply Survey’ started 12 weeks ago - average accuracy rate for € IG of 101%
  • Momentum swung back to Corps today with a large Reverse Yankee
    • Corp (€4.75bn, 56.21%), FIG (€3.2bn, 37.87%) & SSA (€500m, 5.92%) 
  • Avg. FIG € NIC +8.5 vs +11.7 yesterday
  • Avg. Corporate € NIC +7.3 vs +8 yesterday


Corp: Highlights

  • €16.5bn WTD or 99.7% of our ‘Supply Survey’ forecast of €16.55bn
  • American Medical Systems Europe €4.25bn 6-tranche - Deal of the Day
    • Term debt take out of $11bn M&A bridge - US to follow c.$7bn
    • Peak books over €15bn, 3.51 X
    • Final book over €12bn, 2.86 X
    • 2yr FRN NIC of +8 - IPTs to PX - 24.5
    • 2yr NIC of +8 - IPTs to PX -24.5
    • 4yr NIC of +5 - IPTs to PX -30
    • 8yr NIC of +5 - IPTs to PX -27.5
    • 12yr NIC of +10 - IPTs to PX -27.5
    • 20yr NIC of +10 - IPTs to PX -30

FIG: Highlights

  • €14bn WTD or 123.8% of our ‘Supply Survey’ forecast of €11.31bn
  • Danske Bank €1.15bn dual-tranche, Senior Preferred
    • Peak books of over €5.6bn, 5.07 X
    • Final book over €4bn, 3.63 X
    • 2yr FRN NIC of +7 - IPTs to PX -28
    • 5NC4 NIC of +10 - IPTs to PX -30

SSA: Highlights

  • €1.75bn WTD or 40.7% of our ‘Supply Survey’ forecast of €4.3bn
  • Only 2 trades this week
  • Auckland Council €500m (wng) Reg S, 6yr, Green senior secured
    • Final book over €2.25bn, 4.5 X
    • 6yr - IPTs to PX -4


  • UK & European govies all sold off, equities were down again, Brent crude holding & credit indices are tighter
  • Bund’s sold-off across the curve by ~2.5 to 3.5bps, which flattened by ~1bp
  • OAT’s sold-off across the curve by ~4 to 5bps, which steepened by ~1bp
    • OAT vs Bund 10yr spread widened to +152.5 (+149.7 this morning)
  • Gilts sold-off across the curve by ~3 to 4bps, which flattened by ~1bp
  • € swap rates higher by ~2.5 to 3.5bps across the curve
    • € swap spreads were ~0.5bp wider in 5 & 7yrs
  • £ swap rates higher by ~3.5 to 5bps across the curve, which flattened by ~1.5bps 
    • £ swap spreads tighter by ~1bp 
  • € IG priced €8.45bn from 7 deals (2 x Corp, 4 x FIG & 1 x SSA) via 13 tranches
    • €32.25bn WTD or 100.3% of our ‘Supply Survey’ forecast of €32.16bn
  • Swiss Franc delivered Chf125m from 1 deal (1 x Corp) via 1 tranche
  • Sterling (£) & US$ Reg S saw zero activity today
  • iTraxx 5yr Europe & the iTraxx Senior & Sub financial indices are flat to a shade tighter, currently trading at 61.975 (-0.5%), 69.293 (-0.13%) & 115.149(-0.03%) respectively (as we print & % △ on the day)
  • Vix Index rose slightly, currently at 25.23 (24.56 this morning)
  • Brent Crude is largely unchanged on the day, currently at $92.57 (c.$92.34 this morning)
  • European equity bourses are all in the red again with the FTSE, Dax & CAC 40 all down by -0.75%, -0.77% & -0.58% respectively
    • YTD: FTSE ↑5.44%, Dax ↑4.27% & CAC 40 ↓0.61%
  • A breakdown of today’s primary € IG supply is as follows:


  • Corporate (56.21%)
    • Total IG: €4.75bn
    • Avg. tranche size €679
    • Avg. IPT to Pricing -27.71
    • Avg. cover 2.83 X 
  • FIG (37.87%)
    • Total IG: €3.2bn
    • Avg. tranche size €640m
    • Avg. IPT to Pricing -27.7 (unsecured) €1.3bn
    • Avg. IPT to Pricing -5 (covered) €1.9bn
    • Avg. cover 2.38 X 
  • SSA (5.92%)
    • Total IG: €500m
    • Avg. tranche size €500m
    • Avg. IPT to Pricing -4
    • Avg. cover 4.5 X


  • Pipeline:  The European IG pipeline is as follows. 
    • No deals


Contact Stuart Aylward with questions or comments on Bloomberg or via stuart@creditflowresearch.com


Euro IG (today)

Type

Issuer

Size (m)

Structure

Initial Pricing

Final Spd / Yield

IPT to PX

NIC (bp)

Books (m)

Cover 'X'

Corp

American Medical Systems Europe

€500

2yr FRN

3mth € +85 to +90

3mth € +63

-24.5

8

€1,400

2.80 X

Corp

American Medical Systems Europe

€500

2yr

MS+75 to +80

MS+53

-24.5

8

€1,600

3.20 X

Corp

American Medical Systems Europe

€750

4yr

MS+105 area

MS+75

-30

5

€2,200

2.93 X

Corp

American Medical Systems Europe

€750

8yr

MS+135 to +140

MS+110

-27.5

5

€2,500

3.33 X

Corp

American Medical Systems Europe

€1,000

12yr

MS+160 to +165

MS+135

-27.5

10

€2,600

2.60 X

Corp

American Medical Systems Europe

€750

20yr

MS+200 area

MS+170

-30

10

€1,700

2.27 X

Corp

Teollisuuden Voima Oyj

€500

5.25yr EuGB

MS+135 area

MS+105

-30

5

€1,350

2.70 X


  • American Medical Systems Europe B.V. (exp. Issue ratings of A3 / A- / A-) - unconditionally guaranteed by Boston Scientific - brought their anticipated, SEC-registered, senior unsecured, € 6-tranche offering comprising a 2yr FRN & 2, 4, 8, 12 & 20yr fixed-rate notes. Updates will all follow this order. IPTs: 3mth€+85 to +90, MS+75 to +80, MS+105 area, MS+135 to +140, MS+160 to +165 & MS+200 area. The deal launched as follows, all books (pre-rec): 2yr FRN for €500m at 3mth €+63 (>€1.3bn), 2yr for €500m at MS+53 (>€1.8bn), 4yr for €750m at MS+75 (>€2.9bn), 8yr for €750m at MS+110 (>€3.2bn), 12yr for €1bn at MS+135 (>€3.1bn) & the 20yr for €750m at MS+170 (>€2.7bn). Collective final book of €12bn - split: 2yr FRN >€1.4bn), 2yr >€1.6bn, 4yr >€2.2bn, 8yr >€2.5bn, 12yr >€2.6bn & the 20yr >€1.7bn.
    • FAIR VALUE:
      • 2yr FRN @ 3mth € +55  NIC of +8
      • 2yr @ MS+45 NIC of +8
      • 4yr @ MS+70 NIC of +5
      • 8yr @ MS+105 NIC of +5
      • 12yr @ MS+125 NIC of +10
      • 20yr @ MS+160 NIC of +10
    • Today’s deal & the deal to follow later in the US are M&A related, with proceeds to finance the cash consideration of Boston Scientific’s $14.5bn acquisition of Penumbra acquisition - which is expected to close in early Q1 2027. Term debt take-out of $11bn bridge. This € trade is scheduled to be accompanied by a US$ offering today, made up of a 3, 5, 7 & 10yr fixed-rate issue, with Boston Scientific Corp as the specific borrower. Today’s € issuing entity (‘AMSE’) last came to the public bond markets on the 21st of February last year. This €1.5bn dual-tranche was not an M&A related offering, & comprised a €850m 6yr priced at MS+70 (40bps tighter than IPTs from a €2.9bn book); & a €650m 9yr at MS+90 (37.5bps tighter than IPTs from a €2.3bn book).  Worth noting that Moody’s upgraded AMSE’s senior unsecured debt rating to A3 from Baa1 in May of last year. Boston Scientific Corp is an American multinational biomedical engineering firm that develops, manufactures & markets specialized medical devices used in interventional medical specialties such as cardiology, endoscopy, urology & neuromodulation.
  • Teollisuuden Voima Oyj (exp. Issue ratings of Baa3 / BBB- by Moody’s & S&P), brought a €500m (wng) Senior Unsecured, Reg S Bearer, European Green Bond, 5.25yr (26th February 2032). IPTs were in the area of MS+135. Books were in excess of €1.7bn (pre-rec) & the trade launched for €500m at MS+105. Final books were over€1.35bn.
    • FAIR VALUE:
      • 3yr @ MS+100  NIC of +5
    • This is their first public € offering of 2026, having last come to market on the 8th of September last year with a €500m, 7.5yr, EuGB, senior unsecured trade at MS+125 (35bps tighter than IPTs from a €1.75bn book). Prior to that we have to go back to the 23rd of May 2023, when they priced a €600m 7yr at MS+165 (20bps tighter than IPTs from a €1.7bn book). TVO is a Finnish nuclear power company that generates electricity at cost for its shareholders (primarily Finnish industrial & energy companies) through its 3 nuclear reactor units at its Olkiluoto Nuclear Power Plant.


Type

Issuer

Size (m)

Structure

Initial Pricing

Final Spd / Yield

IPT to PX

NIC (bp)

Books (m)

Cover 'X'

FIG

Rabobank

€1,500

3yr EuGB Covered

MS+16 area

MS+10

-6

1

€2,250

1.50 X

FIG

Banca Sella SpA

€400

Long 4yr Covered

MS+47 area

MS+43

-4

8

€400

1.00 X

FIG

Danske Bank

€500

2yr FRN Snr Pref

3mth €+75 area

3mth €+47

-28

7

€2,400

4.80 X

FIG

Danske Bank

€650

5NC4 Snr Pref

MS+95 area

MS+65

-30

10

€1,600

2.46 X

FIG

S-Bank Plc

€150

4NC3 FRN Snr Non-Pref

3mth €+155 area

3mth €+130

-25

-

€320

2.13 X


  • Coöperatieve Rabobank U.A. (exp. Issue ratings of Aaa by Moody’s) brought a 3yr, € benchmark, Dutch Legislative Covered Bond, European Covered Bond (Premium), European Green Bond. Guidance on the trade was in the area of MS+16. Books were first called in excess of €2.25bn (inc. €200m JLMs). Books were in excess of €2.4bn (inc. €200m JLMs) & spread set at MS+10. The deal launched for €1.5bn. The final book was in excess of €2.25bn (inc. €200m JLMs).
    • FAIR VALUE:
      • 3yr @ MS+9  NIC of +1
    • A frequent borrower in multiple currencies, today’s trade is their first public ‘syndicated’ covered offering since the 23rd of January 2024. That trade was a €1.5bn 10yr which priced at MS+37 (6bps tighter than guidance from a €3bn book). There are other more recent ‘self-led’ Dutch Covered trades by the borrower.
  • Banca Sella S.p.A. (exp. Issue rating of AA by S&P) - guaranteed by Sella CB S.r.l. - brought their anticipated €400m (wng), long 4yr (26th January 2031), RegS Bearer, Obbligazioni Bancarie Garantite, European Covered Bond (Premium). IPTs on the deal were in the area of MS+47. Books above €650m (exc. JLMs) & the trade launched for €400m at MS+43. Final books were over €400m.
    • FAIR VALUE:
      • Long 4yr @ MS+35  NIC of +8
    • This is their first covered offering since September 2024 when they priced a €400m 4yr at MS+64 (4bps tighter than guidance from a book of €700m). Worth noting that for this issue Moody’s rated the notes Aa3, & today's is AA by S&P. The bonds are backed by 100% Italian residential mortgages.
  • Danske Bank A/S (exp. Issue ratings of A1 / A+ / AA by Moody’s, S&P & Fitch) brought a € benchmark, unsecured Senior Preferred, Reg S Bearer offering. The 2yr FRN came with IPTs in the area of 3mth €+75. The 5NC4 had IPTs in the area of MS+95. Collective books first cited as above €4bn (exc. JLMs). The 2yr launched for €500m at 3mth €+47, with a book of €3.3bn; the 5NC4 launched for €650m at MS+65, with a book of €2.3bn. Final books were above €2.4bn for the FRN & over €1.6bn for the 5NC4.
    • FAIR VALUE:
      • 2yr FRN @ 3mth €+40  NIC of +7
      • 5NC4 @ MS+55  NIC of +10
    • Danske’s last senior preferred trade was a €400m 2yr FRN in May (tapped for €100m a week later). That deal originally priced at 3mth €+35. Their last broadly syndicated SP public offering was their €1bn 2yr FRN on the 4th of November last year. That priced at 3mth €+32 (23bps tighter than IPTs from a €2.1bn book).
  • S-Bank Plc (exp. Issue ratings of BBB by S&P), brought their expected €150m, 4NC3 Senior Non-Preferred FRN deal. IPTs on the trade were in the area of 3mth€+155. Books were above €320m (exc. JLMs)& the trade launched for €150m at 3mth €+130.
  • >> Size already set to €150m
    • The Finnish retail bank & wealth manager (owned by the S Group retailing coop) has not been in the public markets since December 3rd of last year when they priced a €150m 4NC3 senior non-preferred FRN trade at 3mth €+135 (35bps tighter than IPTs from a €1bn book). Today’s trade is arguably more likely a domestic offering into Finland.


Type

Issuer

Size (m)

Structure

Initial Pricing

Final Spd / Yield

IPT to PX

NIC (bp)

Books (m)

Cover 'X'

SSA

Auckland Council

€500

6yr Green Snr Sec

MS+40 area

MS+36

-4

-

€2,250

4.50 X


  • Auckland Council (exp. Issue ratings of Aa2 / AA by Moody's & S&P), brought their anticipated €500m (wng) Reg S, 6yr, Green senior secured Bearer transaction. IPTs on the trade were in the area of MS+40. Books came in at over €2.25bn (exc. JLMs) & the trade launched & priced for €500m at MS+36.
    • The local government authority of Auckland, New Zealand, is also an active issuer in the Swiss Franc market historically, AC last tapped the public € markets in February of this year with a €500m 10yr senior secured offering which priced at MS+48 (6bps tighter than guidance from a large €8.5bn book).


Week-to-date volumes:

Year-to-date volumes:

Sterling IG (today)


  • No issues.


Week-to-date volumes:

Year-to-date volumes:

Swiss Franc IG (today)

Type

Issuer

Size (m)

Structure

Initial Pricing

Final Spd / Yield

IPT to PX

Corp

Grand City Properties

Chf 125

5yr

SARON MS+160 to +170

SARON MS+170

5


  • Grand City Properties S.A. (exp. Issue rating of BBB by S&P) brought a 5yr, senior unsecured offering with an initial minimum size of Chf100m. Initial pricing was in the range of SARON MS+160 to +170. The deal upsized to Chf125m & priced at SARON MS+170.
    • The borrower has tapped the public € markets twice in 2026 with a €500m senior unsecured & a €600m hybrid. Today’s trade, however, is their first foray back into Swiss Francs in over 7yrs. The legacy Chf130m 5yr matured in June of 2024. ‘GCP’ is a residential real estate company (majority-owned by Aroundtown) that buys, redevelops & manages value-add apartment properties primarily across German cities & London.


Week-to-date volumes:

US$ Reg S (today)


  • No issues.


Pending Deals & Mandates


  • No issues.


Transaction Details


PRICED: Grand City Properties CHF 125m 5yr Sr Unsec; SARON MS+170bp

IGC European Market: Deal Flow - General

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Guidance

Spread

GDNC-PXD

Grand City Properties

5yr

2.305%

3-Dec-31

CHF 125m

Sr Unsec

Fixed

100

2.305%

SARON MS+160/170

SARON MS+170

+5


Reoffer: 5yr: SARON MS+170bp / 100 / 2.305%
Benchmark: 5yr: Govt.+179bp

Launched: 5yr: CHF 125m @ SARON MS+170bp
Guidance: 5yr: SARON MS+160/170bp


  • Issuer: Grand City Properties S.A. (Ticker: GYCGR)
  • Issuer Domicile: Luxembourg
  • Format: Public Fixed Rate Notes
  • Status: Senior unsecured, ranking pari passu
  • Issuer Rating: S&P: BBB (stable outlook)
  • Instrument Rating (exp): S&P: BBB
  • Issue Size (in mm): CHF 125mm
  • Coupon: 2.305% p.a.
  • Maturity: 3-Dec-31 (5 years), 3-month par call
  • Issue Price: 100
  • Spread/Yield: SARON MS +170.0 // YTM 2.305% // Govt.+179
  • ISIN / Security Number: CH1624853201 / 162485320
  • Lead Manager(s): UBS
  • SNB Repo-eligibility: At the discretion of the SNB, expected no
  • Documentation: EMTN Programme Prospectus dated 5-Oct-26 of the Issuer’s Euro Medium Term Note Programme as supplemented on 13-Nov-26 (the “Base Prospectus”)
  • Governing Law: English
  • Covenants: PP, NP, XD
  • SIX Listing: 1-Dec-26
  • Denomination: CHF 5000
  • Sales Restrictions: United States and US persons, United Kingdom, European Economic Area (including Belgium), Japan, Israel, Singapore and Canada, as per the Issuer’s EMTN Programme.


PRICED: Rabobank €1.5bn 3yr CB; MS+10

IGC European Market: Deal Flow - General

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Guidance

Spread

GDNC-PXD

Rabobank

3yr

3.530%

26-Nov-29

€1.5bn

CB

Fixed

100

3.530%

MS+16a

MS+10

-6


Reoffer: 3yr: MS+10bp / 100 / 3.530%
Benchmark: 3yr: OBL 2.5% Oct-29 @ 98.141 / B+34.6bp (HR 104%)

Final Books: In excess of €2.25bn (including €200m JLM). Peak book in excess of €2.4bn (including €200m JLM)

Launched: 3yr: €1.5bn @ MS+10bp - Books in excess of €2.4bn (including €200m JLM)
Spread set at: 3yr: MS+10bp - Books in excess of €2.4bn (including €200m JLM)
Book Update: Books in excess of €2.25bn (including €200m JLM)
Guidance: 3yr: MS+16a


  • Issuer: Coöperatieve Rabobank U.A. ("Rabobank")
  • LEI: DG3RU1DBUFHT4ZF9WN62
  • Guarantor: Rabo Covered Bond Company B.V.
  • Issuer Ratings: Aa3 (Stable) / A+ (Positive) / AA- (Stable) (Moody's / S&P / Fitch)
  • Expected Issue Rating: Aaa (Moody's)
  • Status: Dutch Legislative Covered Bond, European Covered Bond (Premium)
  • Currency: Euro ("EUR")
  • Issue Size: €1.5bn
  • Pricing Date: 19-Nov-26
  • Settlement Date: 26-Nov-26 (T+5)
  • Maturity Date: 26-Nov-29 (soft bullet)
  • Extended Due for Payment Date: 26-Nov-30
  • Reoffer: MS+10bp / 100 / 3.530%
  • Benchmark: OBL 2.5% Oct-29 @ 98.141 (+34.6bps / HR: 104%)
  • Coupon: 3.530% Fixed, Annual, Actual/Actual, ICMA, Following, Unadjusted
  • Coupon for Extended Period: 1 month EURIBOR plus re-offer spread per annum payable monthly in arrear (Screen Rate Determination)
  • Day Count Fraction: Actual/Actual, ICMA
  • Day Count Fraction for Extended Period: Actual/360
  • Business Day Convention: Following, Unadjusted basis
  • Business Day Convention for Extended Period: Modified Following, adjusted
  • Business Days: T2, Amsterdam
  • Coupon Payment Dates:
    • 26 November in each year, commencing on 26-Nov-27 up to and including the Maturity Date
    • The 26th day of each month in the Extended Period, up to and including the Extended Due for Payment Date
  • Put / Call Feature: None
  • Redemption: 100%
  • Denominations: €100,000 (+ €100,000 increments)
  • Listing: Luxembourg Stock Exchange Regulated Market
  • Clearing: Euroclear / Clearstream Luxembourg
  • Use of Proceeds: An amount equal to the proceeds of the European Green Bond will be used to finance and/or refinance, in part or in whole, a portfolio of eligible green assets in accordance with the Issuer's European Green Bond Factsheet prepared by the Issuer in accordance with Annex I of Regulation (EU) 2023/2631 of the European Parliament and of the Council of 22-Nov-23 (the "European Green Bond Regulation").
  • Governing Law: Dutch
  • Type of Note: Bearer, New Global Note
  • ISIN / Common Code: XS3578939681 / 357893968
  • Joint-Lead Managers: BNP Paribas, Commerzbank, DZ Bank, LBBW, Rabobank, Santander and Société Générale
  • Documentation: Final Terms as stated in the base prospectus consisting of separate documents (i.e. (i) the securities note dated 19-May-26 (the "Securities Note") and (ii) the registration document of the Issuer dated 19-May-26, as both supplemented from time to time (the "Registration Document" and together with the Securities Note, the "Base Prospectus")) pertaining to the €35,000,000,000 Covered Bond Programme, guaranteed as to payments of interest and principal by Rabo Covered Bond Company B.V.
  • Selling Restrictions: There are selling restrictions in relation to the United States, the European Economic Area (including the Netherlands, Italy, Luxembourg, Belgium, France, Norway, Sweden and Switzerland), the United Kingdom and Japan. Other restrictions may apply in connection with the offering and sale of a particular Tranche or Series. See the "Subscription and Sale" section in the Base Prospectus
  • US Selling Restrictions: Reg S / TEFRA D
  • Prohibition of Sales to Retail Investors: Applicable. No EU PRIIPs key information document (KID) or UK CCI product summary has been prepared as not available to retail in EEA or in the UK
  • Target Market: MiFID II / UK MiFIR professionals/ECPs-only – Manufacturer target market (MIFID II / UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels)
  • Advertisement: The Base Prospectus is available at https://www.rabobank.com/about-us/investor-relations/funding-and-capital/issuance-programs/covered-bond-program. The Final Terms relating to the securities, when published, will be available at www.luxse.com
  • Fees: The Joint Lead Managers will be paid a fee in connection to the transaction. Details of the fee may be available to investors upon request from your usual contact sales.
  • TOE: 13:03 UKT / 14:03 CET
  • FTT: 13:20 UKT / 14:20 CET


Covered EuGB
3yr (Nov 2029) @ MS+16a

Implied Spread for fresh 3yr @ MS+9
Priced at MS+10
NIC of +1


Comps

TICKER

CPN

ISSUE DATE

MATURITY

Tenor

SIZE

Mid I-spd

ESG

MUNHYP

2.875

16/06/2026

05/07/2029

2.6yr

625

3

N

BYLAN

2.75

22/06/2026

22/06/2029

2.6yr

500

5

N

MUNHYP

3.5

23/11/2026

23/11/2029

3.0yr

500

6

Y


PRICED: Banca Sella €400m Long 4yr CB; MS+43bp

IGC European Market: Deal Flow - General

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Spread

IPT-PXD

Banca Sella

Long 4yr

3.750%

26-Jan-31

€400m

CB

Fixed to Floating

99.608

3.850%

MS+43

-4


Reoffer: Long 4yr: MS+43bp / 99.608 / 3.850%
Benchmark: Long 4yr: OBL 2.2 10-Oct-30 @ 96.375 / B+64.2bp / HR 108%

Tranche 1 (Long 4yr): Final Books above €400m. Peak book above €650m (excl JLMs)

Launched: Long 4yr: €400m @ MS+43bp - Books above €650m (excl JLMs)
Spread set at: Long 4yr: MS+43bp
IPTs: Long 4yr: MS+47a


  • Issuer: Banca Sella S.p.A. (the “Issuer”)
  • Guarantor: Sella CB S.r.l.
  • Issuer / Guarantor LEI Codes: 549300I7OIUB41P86L19 / 8156000AB686AB664518
  • Issue Type: Obbligazioni Bancarie Garantite – European Covered Bond (Premium)
  • Form of Notes: Reg S Bearer, Dematerialized
  • Issuer Ratings (S&P/DBRS): BBB- (Stable) / BBBL (Positive)
  • Expected Issue Rating (S&P): AA
  • Issue Size: €400m
  • Eligibility: ECB eligible, LCR Level 2A, beneficial treatment under CRR Art.129 & Solvency II
  • Pricing Date: 19-Nov-26
  • Settlement Date: 26-Nov-26 (T+5)
  • Maturity Date: 26-Jan-31 (Long 4yr – soft bullet with 12 months extension)
  • Extended Maturity Date: 26-Jan-32
  • Reoffer: MS+43bp / 99.608 / 3.850%
  • Benchmark: OBL 2.2 10-Oct-30 + 64.2 bps (96.375%, HR 108%)
  • Coupon: 3.750% per annum, payable annually in arrears, and accruing from (and including) the Settlement Date to (but excluding) the Maturity Date. 1 month Euribor +43bps Act/360 from (and including) the Maturity Date to (but excluding) the Extended Maturity Date
  • First Interest Payment Date: 26-Jan-28 (Long First Coupon)
  • Fixed Rate Business day convention: Actual/Actual (ICMA), following
  • Floating Rate Business day convention: Actual/360, modified following
  • Business Day: T2 System
  • Redemption: 100% of the Issue Size
  • Clearing: Euronext Securities Milan (Monte Titoli) / Euroclear / Clearstream
  • Listing: Luxembourg Stock Exchange
  • Minimum Denominations: €100,000 + integral multiples of €1,000 in excess thereof
  • Status of the Covered Bonds: The Covered Bonds constitute direct, unconditional, unsecured and unsubordinated obligations of the Issuer and will rank pari passu without preference among themselves and (save for any applicable statutory provisions) at least equally with all other present and future unsecured and unsubordinated obligations of the Issuer from time to time outstanding. In the event of a compulsory winding-up (liquidazione coatta amministrativa) of the Issuer, any funds realised and payable to the Bondholders will be collected by the Guarantor on their behalf and will be included in the Cover Pool, in accordance with the provisions of Article 7-quaterdecies, paragraph 3 of the Law 130/99
  • Target Market: Manufacturers target market (MIFID II / UK MiFIR product governance) is eligible counterparties and professional investors only (all distribution channels). No EU PRIIPs key information document (KID) or UK disclosure document required by the FCA Product Disclosure Sourcebook (DISC) has been prepared as not available to retail in EEA and the UK
  • Governing law: Italian Law
  • Global Coordinator: Mediobanca
  • Joint Lead Managers: Crédit Agricole CIB, IMI–Intesa Sanpaolo, Mediobanca, UniCredit (B&D)
  • ISIN: IT0005734196
  • Documentation: Issued off the Issuer’s Euro 3 billion Covered Bond Programme dated 29-Sep-26 and supplemented on 07-Oct-26 and 11-Nov-26, unconditionally and irrevocably guaranteed as to payments of interest and principal by Sella CB S.r.l.
  • Timing: PRICED. TOE 14.05 CET / FTT 14.15 CET
  • Fees: The Joint Lead Managers will be paid a fee in respect of the transaction


Covered
L 4yr (Jan 2031) @ MS+47a

Implied Spread for fresh L 4yr @ MS+35
Priced at MS+43
NIC of +8


PRICED: Auckland Council €500m 6yr Snr Sec; MS+36bp

IGC European Market: Deal Flow - SSA

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

ISIN

Price

Yield

Spread

IPT-PXD

Auckland Council

6yr

3.75%

30-Nov-32

€500m

Snr Sec

Fixed

XS3567713030

99.868

3.775%

MS+36

-4


Reoffer: 6yr: MS+36bp / 99.868 / 3.775%

Tranche 1 (6yr): Peak book in excess of €2.25bn (excl JLM)

Launched: 6yr: €500m @ MS+36bp - Books in excess of €2.25bn (excl JLM)
IPTs: 6yr: MS+40a


  • Issuer: Auckland Council
  • Issuer LEI: 213800RWHTSELJS5LA96
  • Issuer Ratings: AA (Positive) / Aa2 (Negative) (S&P / Moody's)
  • Exp. Issue Rating: AA / Aa2 (S&P / Moody's)
  • Format: Green Senior Secured Reg S Bearer, Cat1, TEFRA D
  • Security: The obligations of the Issuer under the Notes and the Trust Deed are secured pursuant to the Debenture Trust Deed between Auckland Council and Trustees Executors Limited dated 2-Dec-10 (as amended, restated or supplemented from time to time) with respect to the Charged Assets (as defined in the Debenture) through the issue of Security Stock (as defined in the Debenture) to the Trustee
  • Size: €500m
  • Settlement: 30-Nov-26 (T+7)
  • Maturity: 30-Nov-32 (6yr)
  • Coupon: 3.75% Fixed, Annual, Act/Act (ICMA), Unadjusted, Following
  • Reoffer: MS+36bp / 99.868 / 3.775%
  • Listing / Law: SGX-ST / English
  • Denominations: €200k + €1k
  • Documentation: Issuer's US$10bn Secured Medium Term Note Programme dated 2-Oct-26
  • Target Market: Professional Clients and Eligible Counterparties only (all distribution channels permitted by applicable law). No EEA PRIIPs KID or CCI product summary – No EEA PRIIPs key information document (KID) or CCI product summary has been prepared as not available to retail in EEA or the UK
  • Use of Proceeds: The proceeds will be allocated in accordance with the Sustainable Finance Framework dated Sep-26 (as updated from time to time) (“Framework”) to the financing of planned projects and activities with positive environmental outcomes, which are expected to contribute to a low carbon and climate resilient future, or refinance of corporate debt that supports such projects and activities (as referenced in the Framework) (the “Eligible Projects”)
  • Framework: https://www.aucklandcouncil.govt.nz/content/dam/ac/docs/about-council/investors/sustainable-finance-framework.pdf https://www.aucklandcouncil.govt.nz/content/dam/ac/docs/about-council/investors/iss-corporate-second-party-opinion.pdf
  • ISIN: XS3567713030
  • Joint Lead Managers: Citi (B&D), HSBC, UBS Investment Bank, Westpac
  • Timing: Today’s business
  • Advertisement: The Offering Circular, any Supplements and Final Terms, when published, are available on the website of the SGX: https://www.sgx.com/securities/prospectus-circulars-offer-documents?value=AUCKLAND%20COUNCIL


PRICED: Teollisuuden Voima Oyj €500m 5.25yr Sr Unsec; MS+105bp

IGC European Market: Deal Flow - General

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Spread

IPT-PXD

ISIN

Teollisuuden Voima Oyj

5.25yr

4.375%

26-Feb-32

€500m

Sr Unsec

Fixed

99.568

4.473%

MS+105

-30

XS3579992515


Reoffer: 5.25yr: MS+105bp / 99.568 / 4.473%
Benchmark: 5.25yr: DBR 0 15-Feb-32 @ 84.64 / B+123.3bp (HR: 107%)

Final Books: >€1.35bn. Peak book >€1.7bn (pre-rec)

Launched: 5.25yr: €500m @ MS+105bp
IPTs: 5.25yr: MS+135a


  • Issuer: Teollisuuden Voima Oyj (Ticker: TVOYFH; Country: FI)
  • Issuer LEI: 743700LQ48IZBTZN4S52
  • Issuer Rating: Baa3/BBB- (stb/stb) by Moody's/Fitch
  • Issue Rating (exp.): Baa3/BBB- by Moody's/Fitch
  • Format: Senior Unsecured, Reg S Bearer, NGN, EuGB
  • Selling Restrictions: As per the Programme (Reg S only – Cat 2 / TEFRA D Rules)
  • Trade Date: 19-Nov-26
  • Settlement Date: 26-Nov-26 (T+5)
  • Maturity Date: 26-Feb-32 (5.25-years)
  • Size: €500m
  • Reoffer: MS+105bps / Yld. 4.473% / Px. 99.568%
  • Coupon: 4.375%, FXD, Ann., Act/Act (ICMA), short first
  • Benchmark: DBR 0 15-Feb-32 (Px. 84.64) +123.3 (HR: 107%)
  • ISIN: XS3579992515
  • Docs: Issuer’s EUR 5,000,000,000 EMTN programme dated 3-Jun-26
  • Listing: Luxembourg Stock Exchange regulated market
  • Governing Law: English Law
  • Denominations: €100k+1k
  • Early Redemption: 3m Par Call / MWC / Clean-up call (80%) / Tax Call (at par)
  • Make-Whole Call: B+20bps
  • Use of Proceeds: The Notes are European Green Bonds and an amount equal to the net proceeds of the Notes will be applied by the Issuer to finance or refinance in whole or in part economic activities that are environmentally sustainable under Article 3 of the EU Taxonomy Regulation, being:
    • 4.27 – Construction and safe operation of new nuclear power plants, for the generation of electricity or heat, including for hydrogen production, using best available technologies; and
    • 4.28 Electricity generation from nuclear energy in existing installations as described in the European Green Bond Factsheet dated 5-Sep-25.
    The European Green Bond Factsheet and the alignment of the project categories with the EU Taxonomy Regulation were both subject to pre-issuance review by ISS-Corporate. The ISS-Corporate pre-issuance report, dated 5-Sep-25, and the full European Green Bond Factsheet, are both available on the Issuer's website: https://www.tvo.fi/en/index/investors/financing/debtplanning.html
  • Joint Bookrunners: BNP Paribas (B&D), Crédit Agricole Corporate and Investment Bank, Nordea and Swedbank
  • Target Market: Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) or UK CCI product summary (as defined in the FCA Product Disclosure Sourcebook) has been prepared as the Notes are not available to retail in the EEA or the United Kingdom
  • Timing: TOE 14:26 LDN / 15:26 CET , FTT 15:00 LDN / 16:00 CET
  • Advertisement: The EMTN programme dated 03-Jun-26 is available (link below) and the Final Terms for any notes issued, when published, will be available on the website of the Luxembourg Stock Exchange https://www.tvo.fi/material/sites/tvo/sijoittajasivut/r4qc3uirc/TVO_EMTN_U26_-_Base_Prospectus_-_FINAL.pdf The Investor Presentation is available on the Issuer’s website https://www.tvo.fi/material/sites/tvo/sijoittajasivut/tnztb778z/TVO_-_Credit_Investor_Presentation_30_Sep_2026.pdf Any information on, or accessible through, the Issuer’s website or any other website mentioned in this communication or any website directly or indirectly linked to these websites, and the information in the Issuer’s European Green Bond Factsheet or Pre-Issuance Review, has not been verified and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities and does not form a part of the Base Prospectus, save in each case to the extent that any such information is expressly included or incorporated by reference in the Base Prospectus. In addition, no assurance or representation is given by the Joint Bookrunners or any other person to investors as to the suitability or reliability for any purpose whatsoever of any opinion, report or certification of any third party in connection with the offering of the securities.


5.25yr (Feb 2032) @ MS+135a

Implied Spread for fresh 5.25yr @ MS+100
Priced at MS+105
NIC of +5


COMPS

Issuer

M/S/F

ESG

Cpn (%)

Out. (€m)

Issue

Maturity

YTM

Sprd

Teollisuuden Voima Oyj

Baa3/NR/BBB-

-

4.75

600

May-23

Jun-30

3.5y

86

Teollisuuden Voima Oyj

Baa3/NR/BBB-

Green

4.25

600

May-24

May-31

4.5y

88

Teollisuuden Voima Oyj

Baa3/-/BBB-

Green

3.625

500

Sep-25

Mar-33

6.3y

109


PRICED: Danske Bank €1.15bn 2y SP FRN & 5NC4 SP FXD; 3mE+47bp & MS+65bp

IGC European Market: Deal Flow - General

Issuer

Term

Call

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Spread

IPT-PXD

Danske Bank

2y

-

3mE+47bp

27-Nov-28

€500m

SP

Floating

100

-

3mE+47

-28

Danske Bank

5NC4

4y

4.000%

27-Nov-31

€650m

SP

Fixed Rate Reset

99.685

4.087%

MS+65

-30


Reoffer: 2y: 3mE+47bp / 100 5NC4: MS+65bp / 99.685 / 4.087%
Benchmark: 5NC4: OBL 2.2 30 #192 @ 96.316 / B+86.3bp / HR 103%

Tranche 1 (2y FRN): Final Books above €2.4bn. Peak book above €3.3bn
Tranche 2 (5NC4 FXD): Final Books above €1.6bn. Peak book above €2.3bn

Launched:
2y: €500m @ 3mE+47bp - Books above €3.3bn (Combined books above €5.6bn ex JLMs)
5NC4: €650m @ MS+65bp - Books above €2.3bn
Book Update: Books above €4.0bn (Ex JLM's)
IPTs: 2y: 3mE+75a 5NC4: MS+95a


  • Issuer: Danske Bank A/S
  • Ticker: DANBNK
  • Issuer Ratings: A1 (Stable) / A+ (Positive) / AA (Stable) by Moody's / S&P / Fitch
  • Exp. Issue Ratings: A1/A+/AA by Moody's/S&P/Fitch
  • Status: Direct, unconditional, unsubordinated and unsecured Preferred Senior Notes intended to constitute MREL Eligible Liabilities (see Condition 5.1 in the Base Prospectus).
  • Format: Reg S, Bearer, New Global Notes
  • Issue date: 19-Nov-26
  • Settlement: 27-Nov-26 (T+6)
  • Size:
    • 2y: €500m
    • 5NC4: €650m
  • Maturity:
    • 2y: 27-Nov-28
    • 5NC4: 27-Nov-31
  • Call option:
    • 2y: N/A
    • 5NC4: 27-Nov-30
  • Coupon:
    • 2y: 3-month EURIBOR +47 bps, floating, quarterly, payable in arrear, modified following, Actual/360
    • 5NC4: 4.000% Fixed, Annually, Act/Act ICMA. If Call Option not exercised, a reset fixed rate of interest per annum determined as the sum of the prevailing 1-year EUR Mid-Swap Rate plus the Margin, payable annually in arrear.
  • Early Redemtion: The Notes may be redeemed at par (plus accrued and unpaid interest) in case of an MREL Disqualification Event, or a Tax Event
  • Events of Default/Set-off: None
  • Substitution and Variation: Yes. See Base Prospectus.
  • Denoms: €100k + €1k
  • Listing/Clearing: The Irish Stock Exchange plc, trading as Euronext Dublin/Euroclear
  • Governing Law: English Law, except for certain conditions, which will be under the Danish Law. See the Base Prospectus
  • Documentation: Issuer's EUR 35bn EMTN Programme dated 20 March 2026, as supplemented (together, the "Base Prospectus").
  • Use of Proceeds: General Business Purposes.
  • Joint-Lead Manager(s): Crédit Agricole CIB, Danske Bank (B&D), DZ BANK, Lloyds, Natixis, UniCredit
  • Timing: Priced
  • TOE:
    • 2y: 15:48 CET
    • 5NC4: 15:51 CET
  • FTT:
    • 2y: 15:15 UKT / 16:15 CET
    • 5NC4: 15:15 UKT / 16:15 CET
  • Advertisement: Base Prospectus and supplements available at: https://danskebank.com/investor-relations/debt/funding-programmes?section=EMTN, final terms to be available at: https://danskebank.com/investor-relations/debt/debt-issues
  • ISIN:
    • 2y: XS3576811114
    • 5NC4: XS3576811205


Senior Preferred
2yr (Nov 2029) @ 3mE+75a

Implied Spread for fresh 2yr @ 3mE+40
Priced at 3mE+47
NIC of +7


Senior Preferred
NC4yr (May 2030) @ MS+95a

Implied Spread for fresh NC4yr @ MS+55
Priced at MS+65
NIC of +10


COMPS

Ticker

Rating (M/S&P/F)

CPN

Size (m)

Mat

Call dt

Life

I-sprd

CPN

DANBNK

A1/A+/AA

4,125

1000

Jan-31

Jan-30

3,1

56

FXD

DANBNK

A1/A+/AA

3,250

750

Jan-33

Jan-32

5,2

66

FXD

DNBNO

Aa2/AA-/-

3,000

750

Jan-32

Jan-31

4,2

59

FXD

SHBASS

Aa2/AA-/AA+

3,875

750

Oct-30

Bullet

3,9

46

FXD

NDAFH

Aa3/AA-/AA

3,250

1000

Apr-31

Bullet

4,4

54

FXD

Ticker

Rating (M/S&P/F)

CPN

Size (m)

Mat

Call dt

Life

DM

CPN

DANBNK

A1/A+/AA

2,851

500

May-28

Bullet

1,5

36

FRN

SHBASS

Aa2/AA-/AA+

3,116

750

Feb-29

Bullet

2,2

37

FRN

INTNED

A2/A+/AA

3,362

1250

Nov-28

Bullet

2,0

50

FRN

CMZB

A2/A/-

3,405

1250

Nov-28

Bullet

2,0

57

FRN


PRICED: S-Bank €150m 4NC3 SNP FRN; 3mE+130bp

IGC European Market: Deal Flow - General

Issuer

Term

Call

Coupon

Maturity

Size

Ranking

Type

Price

Spread

IPT-PXD

S-Bank

4NC3

3y

3mE+130bp

26-Nov-30

€150m

SNP

Floating

100

3mE+130

-25


Reoffer: 4NC3: 3mE+130bp / 100

Final Books: Peak book above €320m (excl JLMs)

Launched: 4NC3: €150m @ 3mE+130bp - Books above €320m (excl JLMs)
Spread set at: 4NC3: 3mE+130bp
Guidance: 4NC3: 3mE+130+/-5bp WPIR - Books above €305m (incl €12m JLMs)
IPTs: 4NC3: 3mE+155a


  • Issuer: S-Bank plc
  • LEI: 743700FTBNXAUN57RH30
  • Issuer Credit Rating: A- (Stable) by S&P
  • Exp. Ratings: BBB by S&P
  • Status of the Notes: Senior Non-Preferred Notes, direct, unguaranteed and unsecured
  • Pricing Date: 19-Nov-26
  • Settlement Date: 26-Nov-26
  • Maturity Date: 26-Nov-30
  • Optional Redemption Date: 26-Nov-29
  • Size: €150m
  • Reoffer: 3mE+130bps / px: 100%
  • Coupon: 3mE+130bps, Actual/360, Modified Following, Adjusted
  • Early Redemption: Upon the occurrence of an MREL Disqualification Event, a Capital Event or a Tax event as set out in 6.4, 6.5 and 6.6 and subject to the Conditions to Redemption set out in Condition 6.7 being fulfilled
  • Early Redemption at the option of the Issuer: Pursuant to the Condition 6.3, and subject to the Conditions to Redemption set out in the Condition 6.7 being fulfilled, the Issuer may, on giving not less than the minimum period (15 days) and not more than the maximum period (30 days) of prior notice to the Noteholders, redeem all, or some only, of the outstanding Notes on the Optional Redemption Date
  • Substitution and Variation: Yes, as set out in Condition 23
  • Denominations: €100,000 + €100,000
  • ISIN: FI4000626478
  • Clearing: Euroclear Nordics
  • Listing: Nasdaq Helsinki
  • Law: Finnish Law
  • Documentation: The Issuer's EUR 3bn Programme for the Issuance of Senior Preferred Notes, Senior Non-Preferred Notes, Covered Bonds and Additional Tier 1 Capital Notes dated 24-Apr-26, as supplemented on 9-Nov-26
  • Fees: The Joint Bookrunners will be paid a fee by the Issuer in respect of the placement of the Notes
  • Target Market: MiFID II Eligible counterparties and professional clients only / No PRIIPs KID has been prepared as not available to retail in the EEA or United Kingdom
  • Joint Bookrunners: Danske Bank (B&D) and SEB
  • Timing: TOE: 15:09 CET / FTT: Immediately
  • Advertisement: The Final Terms, when published, will be available at https://www.s-pankki.fi/fi/s-pankki-yrityksena/sijoittajille/debt-investors/


COMPS

Security

Tenor/call

Amt (m)

Rating

Issued

Spread (bid)

SPANOY Float 12/11/29

2.1y

150

/BBB

11-Dec-25

113 (DM+)

SBAB 3 3/8 05/21/31

3.5y

500

Baa1/BBB+

21-May-25

77 (I+)

SYDBDC 3 5/8 05/29/31

3.5y

500

A3/

29-May-26

82 (I+)

OPBANK 3 1/4 01/30/32

4.2y

500

Baa1/A

30-Jan-26

91 (I+)

SRBANK 3 3/4 04/21/32

4.4y

500

A3/

21-Apr-26

87 (I+)


PRICED: American Medical Systems Europe B.V. €4.25bn 6-part Sr Unsec; 3mE+63bp & MS+53bp & MS+75bp & MS+110bp & MS+135bp & MS+170bp

IGC European Market: Deal Flow - General

Issuer

Term

Coupon

Maturity

Size

Ranking

Type

Price

Yield

Spread

IPT-PXD

American Medical Systems Europe B.V.

2yr

3mE+63

01-Dec-28

€500m

Sr Unsec

Floating

100

-

3mE+63

-24.5

American Medical Systems Europe B.V.

2yr

3.875%

01-Dec-28

€500m

Sr Unsec

Fixed

99.87

3.944%

MS+53

-24.5

American Medical Systems Europe B.V.

4yr

4.125%

01-Dec-30

€750m

Sr Unsec

Fixed

99.852

4.166%

MS+75

-30

American Medical Systems Europe B.V.

8yr

4.5%

01-Dec-34

€750m

Sr Unsec

Fixed

99.835

4.525%

MS+110

-27.5

American Medical Systems Europe B.V.

12yr

4.75%

01-Dec-38

€1bn

Sr Unsec

Fixed

99.275

4.831%

MS+135

-27.5

American Medical Systems Europe B.V.

20yr

5.125%

01-Dec-46

€750m

Sr Unsec

Fixed

99.3

5.182%

MS+170

-30


Reoffer: 2yr FRN: 3mE+63bp / 100 2yr: MS+53bp / 99.87 / 3.944% 4yr: MS+75bp / 99.852 / 4.166% 8yr: MS+110bp / 99.835 / 4.525% 12yr: MS+135bp / 99.275 / 4.831% 20yr: MS+170bp / 99.3 / 5.182%
Benchmark: 2yr: OBL 2.4 Oct-28 #188 @ 98.545 / B+74.6bp (HR: 105%) 4yr: OBL 2.2 10-Oct-30 #192 @ 96.39 / B+96.3bp (HR: 103%) 8yr: DBR 2.6 15-Aug-34 @ 95.12 / B+120bp (HR: 101%) 12yr: DBR 1 May-38 @ 76.5 / B+130.6bp (HR: 112%) 20yr: DBR 2 ½ 15-Aug-46 @ 82.79 / B+143.3bp (HR: 100%)

Tranche 1 (2yr FRN): Final Books >€1.4bn. Peak book >€1.4bn
Tranche 2 (2yr FXD): Final Books >€1.6bn. Peak book greater than €1.8bn
Tranche 3 (4yr): Final Books >€2.2bn. Peak book greater than €2.9bn
Tranche 4 (8yr): Final Books >€2.5bn. Peak book greater than €3.2bn
Tranche 5 (12yr): Final Books >€2.6bn. Peak book greater than €3.1bn
Tranche 6 (20yr): Final Books >€1.7bn. Peak book greater than €2.7bn
Hedge Deadline: 15:45 UKT / 16:45 CET

Launched:
2yr FRN: €500m @ 3mE+63bp - Books greater than €1.3bn
2yr: €500m @ MS+53bp - Books greater than €1.8bn
4yr: €750m @ MS+75bp - Books greater than €2.9bn
8yr: €750m @ MS+110bp - Books greater than €3.2bn
12yr: €1bn @ MS+135bp - Books greater than €3.1bn
20yr: €750m @ MS+170bp - Books greater than €2.7bn
(Combined Books in excess of €15bn)
IPTs: 2yr FRN: 3mE+85/90bp 2yr: MS+75/80bp 4yr: MS+105a 8yr: MS+135/140bp 12yr: MS+160/165bp 20yr: MS+200a


  • Issuer: American Medical Systems Europe B.V. (Country: NL)
  • Guarantor: Boston Scientific Corporation (Ticker: BSX; Country: US)
  • LEI:
    • Issuer: 549300AA2JE6ZQ5D2493
    • Guarantor: Y6ZDD9FP4P8JSSJMW954
  • Guarantor Ratings: A3 (Negative) by Moody's / A- (Negative) by S&P / A- (Stable) by Fitch
  • Expected Issue Ratings: A3 by Moody's / A- by S&P / A- by Fitch
  • Format: SEC Registered, Senior, Unsecured
  • Settlement: 01-Dec-26 (T+8)
  • Size:
    • 2yr FRN: €500m
    • 2yr: €500m
    • 4yr: €750m
    • 8yr: €750m
    • 12yr: €1bn
    • 20yr: €750m
  • Maturity:
    • 2yr FRN: 01-Dec-28
    • 2yr: 01-Dec-28
    • 4yr: 01-Dec-30
    • 8yr: 01-Dec-34
    • 12yr: 01-Dec-38
    • 20yr: 01-Dec-46
  • Reoffer:
    • 2yr FRN: 3mE+63 / 100
    • 2yr: MS+53 / 99.87 / 3.944%
    • 4yr: MS+75 / 99.852 / 4.166%
    • 8yr: MS+110 / 99.835 / 4.525%
    • 12yr: MS+135 / 99.275 / 4.831%
    • 20yr: MS+170 / 99.3 / 5.182%
  • Coupon:
    • 2yr FRN: 3mE+63 Floating, Qtrly, Act/360
    • 2yr: 3.875% Fixed, Ann, Act/Act (ICMA)
    • 4yr: 4.125% Fixed, Ann, Act/Act (ICMA)
    • 8yr: 4.500% Fixed, Ann, Act/Act (ICMA)
    • 12yr: 4.750% Fixed, Ann, Act/Act (ICMA)
    • 20yr: 5.125% Fixed, Ann, Act/Act (ICMA)
  • Benchmark:
    • 2yr: OBL 2.4 Oct-28 #188 @ 98.545 / 3.198% (HR: 105%)
    • 4yr: OBL 2.2 10-Oct-30 #192 @ 96.39 / 3.203% (HR: 103%)
    • 8yr: DBR 2.6 15-Aug-34 @ 95.12 / 3.325% (HR: 101%)
    • 12yr: DBR 1 May-38 @ 76.5 / 3.525% (HR: 112%)
    • 20yr: DBR 2 ½ 15-Aug-46 @ 82.79 / 3.749% (HR: 100%)
  • Benchmark Spread:
    • 2yr: B+74.6bp
    • 4yr: B+96.3bp
    • 8yr: B+120.0bp
    • 12yr: B+130.6bp
    • 20yr: B+143.3bp
  • MWC:
    • 2yr: B+15
    • 4yr: B+15
    • 8yr: B+20
    • 12yr: B+20
    • 20yr: B+25
  • Par Call:
    • 4yr: 1-month
    • 8yr: 3-month
    • 12yr: 3-month
    • 20yr: 6-month
  • Special Mandatory Redemption: 101% plus accrued interest if the Penumbra Acquisition is not completed by the Special Mandatory Redemption End Date (later of 14-Jan-27, extendable to no later than 14-Jan-28, or five business days after any later agreed Outside Date) or if Boston Scientific will not pursue the acquisition. Proceeds not escrowed
  • B&D: Citigroup
  • TOE:
    • 2yr FRN: 15:57 UKT / 16:57 CET
    • 2yr: 15:56 UKT / 16:56 CET
    • 4yr: 15:55 UKT / 16:55 CET
    • 8yr: 15:54 UKT / 16:54 CET
    • 12yr: 15:53 UKT / 16:53 CET
    • 20yr: 15:53 UKT / 16:53 CET
  • ISIN:
    • 2yr FRN: XS3577499059
    • 2yr: XS3573007385
    • 4yr: XS3573008607
    • 8yr: XS3573008862
    • 12yr: XS3573009167
    • 20yr: XS3573009670
  • Docs: Euronext Dublin GEM Listing / Netherlands (Issuer) & U.S. Law (Guarantor) / €100k and integral multiples of €1k in excess thereof / Tax Call / CoC
  • Clearing: Clearstream Banking S.A. ("Clearstream") and Euroclear Bank SA/NV ("Euroclear")
  • Denominations: €100k and integral multiples of €1k in excess thereof
  • Selling Restrictions: As per Preliminary Prospectus Supplement. Sales to Canada via exemption.
  • UoP: We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
  • Stabilization: Relevant stabilization regulations including FCA/ICMA apply.
  • Target Market: MiFID II and UK MiFIR - professionals/ECPs-only / No EEA PRIIPs key information document (KID) or UK disclosure document required by DISC – Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No EEA PRIIPs KID or UK DISC disclosure document has been prepared as the notes are not available to retail investors in the European Economic Area or the UK.
  • Active Bookrunners: Barclays, Citigroup, and J.P. Morgan
  • Timing: Priced. FTT subject to TS.
  • Advertisement: Any offering of securities will be made only by means of a prospectus supplement, which will be filed with the SEC, and accompanying prospectus. In the event that the company proceeds with an offering, you may obtain a copy of the prospectus supplement for free by visiting EDGAR on the SEC website at https://clicktime.symantec.com/3A2gL34bxV7t6bDgb9gYS6K7GS?u= www.sec.gov [sec.gov]. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it.



2yr (Dec 2029) @ 3mE+85-90

Implied Spread for fresh 2yr @ 3mE+55
Priced at 3mE+63
NIC of +8


2yr (Dec 2028) @ MS+75-80

Implied Spread for fresh 2yr @ MS+45
Priced at MS+53
NIC of +8

4yr (Dec 2030) @ MS+105a

Implied Spread for fresh 4yr @ MS+70
Priced at MS+75
NIC of +5

8yr (Dec 2034) @ MS+135-140

Implied Spread for fresh 8yr @ MS+105
Priced at MS+110
NIC of +5

12yr (Dec 2038) @ MS+160-165

Implied Spread for fresh 12yr @ MS+125
Priced at MS+135
NIC of +10

20yr (Dec 2046) @ MS+200a

Implied Spread for fresh 20yr @ MS+160
Priced at MS+170
NIC of +10


COMPS

A Rated Med-Tech

Bond

Rating (M/S&P/F)

Issue Dt.

Amt

Tenor

I-spread

BSX 1.375 3/28

A3 / A- / A-

Mar-22

€750mm

1.3yr

ms+38bp

BSX 3.375 3/29

A3 / A- / A-

Feb-24

€750mm

2.3yr

ms+51bp

BSX 3.000 3/31

A3 / A- / A-

Feb-25

€850mm

4.3yr

ms+70bp

BSX 1.625 3/31

A3 / A- / A-

Mar-22

€750mm

4.3yr

ms+67bp

BSX 3.500 3/32

A3 / A- / A-

Feb-24

€1250mm

5.3yr

ms+80bp

BSX 3.250 3/34

A3 / A- / A-

Feb-25

€650mm

7.3yr

ms+97bp

BSX 1.875 3/34

A3 / A- / A-

Mar-22

€500mm

7.3yr

ms+91bp

DHR 0.750 9/31

A2 / A- / -

Sep-19

€1750mm

4.8yr

ms+55bp

DHR 3.625 4/34

A2 / A- / -

Apr-26

€750mm

7.5yr

ms+78bp

DHR 4.000 4/38

A2 / A- / -

Apr-26

€1000mm

11.5yr

ms+96bp

DHR 1.800 9/49

A2 / A- / -

Sep-19

€750mm

22.9yr

ms+129bp

MDT 3.650 10/29

A3 / A / -

Jun-24

€850mm

2.9yr

ms+38bp

MDT 2.950 10/30

A3 / A / -

Sep-25

€750mm

3.9yr

ms+48bp

MDT 3.875 10/36

A3 / A / -

Jun-24

€850mm

9.9yr

ms+81bp

MDT 4.150 10/43

A3 / A / -

Jun-24

€600mm

16.9yr

ms+131bp

MDT 4.200 10/45

A3 / A / -

Sep-25

€750mm

18.9yr

ms+141bp

SYK 3.375 9/32

A3 / BBB+ / -

Sep-24

€800mm

5.8yr

ms+71bp

SYK 3.625 9/36

A3 / BBB+ / -

Sep-24

€600mm

9.8yr

ms+91bp

TMO 3.628 12/35

A2 / A- / A-

Dec-25

€1100mm

9.0yr

ms+81bp

TMO 1.875 10/49

A2 / A- / A-

Sep-19

€1000mm

22.9yr

ms+138bp

TMO 2.000 10/51

A2 / A- / A-

Oct-21

€750mm

24.9yr

ms+137bp

Other Recent Healthcare

Bond

Rating (M/S&P/F)

Issue Dt.

Amt

Tenor

I-spread

GSK 3.500 9/30

A2 / A / -

Sep-26

€1000mm

3.8yr

ms+51bp

GSK 3.875 9/34

A2 / A / -

Sep-26

€850mm

7.8yr

ms+76bp

GSK 4.125 9/37

A2 / A / -

Sep-26

€800mm

10.8yr

ms+96bp

MRKGR 3.875 5/31

A3 / A / -

Nov-26

€900mm

4.5yr

ms+58bp

MRKGR 4.125 11/33

A3 / A / -

Nov-26

€1050mm

7.0yr

ms+78bp

MRKGR 4.250 11/36

A3 / A / -

Nov-26

€1050mm

10.0yr

ms+97bp

Healthcare FRNs

Bond

Rating (M/S&P/F)

Issue Dt.

Amt

Tenor

Spread

DHR FRN 4/28

A2 / A- / -

Apr-26

€500mm

1.4yr

3mE+36bp

GSK FRN 3/28

A2 / A / -

Sep-26

€850mm

1.3yr

3mE+31bp

MRKGR FRN 11/28

A3 / A / -

Nov-26

€700mm

2.0yr

3mE+43bp

TMO FRN 12/27

A2 / A- / A-

Dec-25

€1000mm

1.0yr

3mE+35bp



To view the LIVE / REAL TIME European IG pipeline please click here.

Details correct at time of posting

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.